Search

Halozyme Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

98.41 -1.89

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

97.9

Max

100.55

Pagrindiniai rodikliai

By Trading Economics

Pajamos

80M

230M

Pardavimai

104M

481M

P/E

Sektoriaus vid.

30.182

57.002

Pelnas, tenkantis vienai akcijai

2.17

Pelno marža

47.799

Darbuotojai

423

EBITDA

100M

320M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

-4.98% downside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.9B

12B

Ankstesnė atidarymo kaina

100.3

Ankstesnė uždarymo kaina

98.41

Naujienos nuotaikos

By Acuity

50%

50%

163 / 340 reitingas Healthcare

Halozyme Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 20:06; UTC

Halozyme Therapeutics Inc shares are lower amid broader market concerns following a decline in U.S. retail sales, continuing a trend of volatility.

2026-08-13 19:56; UTC

Halozyme Therapeutics Inc shares are lower during Thursday's session, having retraced from an earlier peak with no specific news to explain the decline.

2026-08-12 19:16; UTC

News

Halozyme Therapeutics Inc shares are lower, pressured by a high Relative Strength Index indicating potential overbought conditions amid recent market sentiment.

2026-08-11 20:02; UTC

News

Halozyme Therapeutics reported strong second-quarter earnings, raising full-year revenue guidance to $1.87 billion. Shares are trading roughly flat amid high trading volume.

2026-08-10 22:36; UTC

Halozyme Therapeutics shares are higher in after-market trading, reaching a high above the 20-day moving average and near the upper end of its one-month range.

2026-08-07 23:21; UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

2026-08-06 23:51; UTC

News
Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

2026-08-05 22:16; UTC

Halozyme Therapeutics shares are lower in after-market trading, reflecting broader market pressures amid mixed sentiment from geopolitical developments and weak employment data.

2026-08-04 19:22; UTC

News

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.

2026-08-03 19:46; UTC

Halozyme Therapeutics Inc. shares are lower today, despite earlier gains, amid a broader market rally following a significant drop in oil prices.

2026-07-31 20:06; UTC

Shares of Halozyme Therapeutics are lower today, reflecting broader market trends amid rising U.S. Treasury yields and crude oil prices influencing inflation concerns.

2026-07-30 19:58; UTC

Halozyme Therapeutics Inc shares are higher, reflecting a broader recovery in technology stocks amid improved market sentiment. The stock remains near its one-month range.

2026-07-29 19:27; UTC

Social Media

Halozyme shares are higher today, despite earlier pulling back. Recent commentary raises concerns about future performance and potential writedowns from acquisitions.

2026-07-28 20:03; UTC

Halozyme Therapeutics Inc. is trading higher, benefiting from a broader upward trend in biotechnology stocks, despite a pullback earlier in the session.

2026-07-27 19:46; UTC

Shares of Halozyme Therapeutics Inc. are lower today, continuing a decline since Friday. Broader market sentiment is affected by a drop in crude oil prices.

2026-07-24 20:07; UTC

News

Halozyme Therapeutics is gaining traction as shares rise, supported by strong cash flow margins and revenue growth. The stock is currently priced at $80.60 per share.

2026-07-22 19:35; UTC

Halozyme Therapeutics shares are lower today, despite an earlier peak gain. The decline follows a drop since Tuesday's close amid rising crude oil prices.

Akcijų palyginimas

Kainos pokytis

Halozyme Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

-4.98% į apačią

12 mėnesių prognozė

Vidutinis 93.75 USD  -4.98%

Aukščiausias 115 USD

Žemiausias 57 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Halozyme Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

5

Pirkti

2

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

163 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat